Activity Description & Educational Objectives
In this activity based on a recent live webcast, Dr. Sagar Lonial discusses strategies for improving patient care in multiple myeloma, including tools for recognizing and addressing treatment-related toxicity and selecting therapy designed to overcome poor-prognosis features. Other discussion topics will include updates on new clinical evidence for the selection and use of primary therapy for transplant-eligible and -ineligible patients, a discussion of recent data on therapy for relapsed/refractory disease, as well as an assessment of next-generation therapeutics, from emerging proteasome inhibitors and other targeted agents to innovative, antibody-based approaches.
Upon completion of this activity, participants will be able to:
- Explain the clinical benefits and potential toxicity of novel treatment options to patients with multiple myeloma preparing to receive treatment
- Identify and/or select patient-appropriate upfront and/or maintenance/consolidation therapy for transplant-eligible or -ineligible patients with newly diagnosed multiple myeloma
- Recommend therapy for patients with relapsed/refractory myeloma according to patient needs, disease aggressiveness, and treatment history, among other factors
- Summarize safety and efficacy data on established and emerging novel strategies currently being tested across myeloma treatment settings
- Communicate adverse event management strategies to patients with myeloma, and intervene to manage or prevent treatment-related toxicity in the myeloma setting
This activity has been designed to meet the educational needs of hematologist-oncologists, oncologists, hematologists, advanced practice oncology nurses, and other clinicians involved in the management of patients with multiple myeloma.
Requirements for Successful Completion
In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no pre-requisites and there is no fee to participate in this activity or to receive CME/CNE credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.
Release and Expiration Dates: May 08, 2014 - May 07, 2015
Time to Complete: 60 minutes
Faculty & Disclosure / Conflict of Interest Policy
In accordance with ACCME requirements, Penn State College of Medicine has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.
Course Director and Moderator
Sagar Lonial, MD
Professor and Vice Chair of Clinical Affairs
Department of Hematology and Medical Oncology
Winship Cancer Institute
Sagar Lonial, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for Bristol-Myers Squibb; Celgene Corporation; Millennium Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; Onyx Pharmaceuticals, Inc.; and sanofi-aventis.
PVI, PeerView Institute for Medical Education
Carmine DeLuca has no financial interests/relationships or affiliations in relation to this activity.
Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.
Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.
Sponsorship, Credit & Support
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine and PVI, PeerView Institute for Medical Education. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
The Penn State College of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Information about CME credit for this activity is available by contacting Penn State at 717-531-6483 or ContinuingEd@hmc.psu.edu. Reference course # G5541-14-T.
The Institute for Advancement of Human Behavior is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. This course is co-provided by IAHB and PVI, PeerView Institute for Medical Education. Maximum of 1.0 contact hour(s).
This CME/CNE activity is jointly provided by Penn State College of Medicine and PVI, PeerView Institute for Medical Education; the activity is also co-provided by the Institute for Advancement of Human Behavior.
This activity is supported by educational grants from Bristol-Myers Squibb, Celgene Corporation, Millennium: The Takeda Oncology Company and Onyx Pharmaceuticals, Inc.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.
No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.
Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.